Injectable calcium phosphate in the treatment of distal radial fractures.
An injectable material which hardened in situ to form a carbonated hydroxyapatite, Norian SRS (Norian Corp., Cupertino, USA), was used as the only treatment of unstable distal radial fractures in six patients. Except for an external dorsal splint for 2 weeks, no other treatment was used. The material maintained reduction except in one case in which there were technical problems during hardening and the material fragmented postoperatively. By 1 year all patients had a satisfactory clinical outcome. There was an early return of motion. The possibility of mobilization 1 or 2 weeks after the operation may reduce postoperative stiffness and increase short-term functional outcome.
Kopylov
P
P
Department of Orthopedics, University Hospital, Lund, Sweden.
Jonsson
K
K
Thorngren
K G
KG
Aspenberg
P
P
D001031:Apatites; D018786:Bone Substitutes; D002130:Calcium Phosphates / Q000008:administration & dosage*; D005500:Follow-Up Studies; D017102:Fracture Healing / Q000502:physiology; D006801:Humans; D007267:Injections; D011183:Postoperative Complications / Q000000981:diagnostic imaging; D011403:Pronation / Q000502:physiology; D011859:Radiography; D011885:Radius Fractures / Q000000981:diagnostic imaging / Q000601:surgery*; D016059:Range of Motion, Articular / Q000502:physiology; D012008:Recurrence; D014954:Wrist Injuries / Q000000981:diagnostic imaging / Q000601:surgery*
D001031:Apatites; D018786:Bone Substitutes; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C030782:carboapatite; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous